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Abstract 
Causative mutations and variants associated with cardiac 
diseases have been found in genes encoding cardiac ion 
channels, accessory proteins, cytoskeletal components, 
junctional proteins, and signaling molecules. In most 
cases the functional evaluation of the genetic alteration 
has been carried out by expressing the mutated proteins 
in in-vitro  heterologous systems. While these studies 
have provided a wealth of functional details that have 
greatly enhanced the understanding of the pathological 
mechanisms, it has always been clear that heterologous 
expression of the mutant protein bears the intrinsic 
limitation of the lack of a proper intracellular environment 
and the lack of pathological remodeling. The results 
obtained from the application of the next generation 
sequencing technique to patients suffering from cardiac 
diseases have identified several loci, mostly in non-coding 
DNA regions, which still await functional analysis. The 
isolation and culture of human embryonic stem cells has 
initially provided a constant source of cells from which 
cardiomyocytes (CMs) can be obtained by differentiation. 
Furthermore, the possibility to reprogram cellular fate 
to a pluripotent state, has opened this process to the 
study of genetic diseases. Thus induced pluripotent 
stem cells (iPSCs) represent a completely new cellular 
model that overcomes the limitations of heterologous 
studies. Importantly, due to the possibility to keep 
spontaneously beating CMs in culture for several months, 
during which they show a certain degree of maturation/
aging, this approach will also provide a system in which 
to address the effect of long-term expression of the 
mutated proteins or any other DNA mutation, in terms 
of electrophysiological remodeling. Moreover, since 
iPSC preserve the entire patients’ genetic context, the 
system will help the physicians in identifying the most 
appropriate pharmacological intervention to correct the 
functional alteration. This article summarizes the current 
knowledge of cardiac genetic diseases modelled with 
iPSC.
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fibroblast was reprogrammed to a cell that assumed the 
main characteristics of an ESC: high proliferation rate 
as well as wide differentiation potential toward the three 
germ layers. Nevertheless, the search for an identical 
physiological counterpart has lead to the conclusion that 
these induced pluripotent stem cells (iPSCs), although 
very similar to ESCs, must be considered as artificial 
cells created in the lab. In 2007, the same process was 
applied successfully to human fibroblasts by Yamanaka’
s as well as Thomson’s group[2,3], thus creating cell lines 
that can be propagated almost indefinitely and can 
be used, in a close future, as a continuous source of 
differentiated cells for therapeutic purposes.
The application of this powerful technique to 
humans opened the possibility to reprogram fibroblasts 
isolated not only from healthy people but also from 
patients suffering of a genetic disease. The resulting 
human iPSCs (hiPSC) will keep the entire genetic 
information of the patient, including the mutation that 
has been linked to the pathology. The first examples of 
disease-related hiPSC involved patients with a range 
of human genetic diseases, whose DNA mutations, 
including the trisomy 21, were effectively maintained 
through all the reprogramming procedure[4].
Since then, many laboratories started to model 
in vitro human genetic disease, succeeding to get a 
considerable number of post-mitotic cells for detailed 
functional studies. Indeed, this result is particularly 
important and useful when studying affected human 
cardiomyocytes or neurons, otherwise difficult to be 
obtained and maintained in culture. In most cases, 
despite the fact that hiPSC-derived cells are not 
exactly equal to the physiological counterpart, the 
system has attested successful in vitro replication of 
the main cellular characteristics already known to be 
associated with the modeled disease. 
In this review we will discuss the important 
discoveries of the biological mechanisms underlying 
some genetic cardiomyopathies, made possible by 
the use of the cellular reprogramming technology.
From pluripotent stem cells to 
spontaneously contractile cells
In vitro development of ESCs has been widely studied 
using murine ESCs (mESCs), whose differentiation 
procedure in culture implies the initial leukemia inhibitory 
factor (LIF) removal and the formation of cellular 
aggregates using the “hanging drop” method. These 
three dimensional (3D) structures, called embryoid 
bodies (EBs), replicate in vitro the different stages of 
murine embryonic development[5]. Around differentiation 
day (dd) 8, clusters of spontaneously beating cells appear 
in culture; these cells express several transcriptional and 
structural cardiac markers and were therefore classified 
generically as cardiomyocytes[6]. It should be noted that 
mESC differentiation starts by just removing LIF also in 
a 2D culture, but the resulting process does not strictly 
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Core tip: This paper revises the cardiac genetic diseases 
that have been modeled so far using the technology that 
starts from patient somatic cells, reprogram their fate to 
a pluripotent state, and then proceed to cardiomyocyte 
differentiation. We will describe the main steps of 
this procedure, from pluripotent stem cells to mature 
cardiomyocytes, and we will discuss the main features 
linked to the different cardiac pathologies that this model 
recapitulate in a cell culture dish.
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introDuction
In 19th century, the Italian physician Giulio Bizzozero, 
founder of the Italian school of experimental pathology, 
proposed the classification of tissues depending on 
their regeneration rate. He divided human tissues in 
three categories: labile, stable, and perennial, where 
the labile are physiologically subjected to a continuous 
renewal, e.g., keratinocytes, or bone marrow cells; 
stables, that are normally in a quiescent state but still 
retain the capacity to proliferate, e.g., hepatocytes; 
and perennial, the so-called post-mitotic cells, that 
have completely lost their regenerative potential. 
The most representative cells in the latter case are 
neurons and cardiomyocytes, highly specialized cells 
that, apart from their duplication inability, share also 
the capacity, during development, to connect to sister 
cells and to build an organized network capable of an 
electric signal transmission. 
During these years we learned the methods to 
cultivate and to maintain labile and stable cells in 
culture, but neurons and cardiomyocytes are still 
“problematic” cells, difficult to preserve in absence of 
their natural support, glial cells or cardiac fibroblasts, 
and, moreover, almost impossible to be obtained as 
sample from a healthy person. 
Progress in this field came from studies of develo 
pmental biologist that were able to isolate, cultivate, and 
differentiate adult or embryonic stem cells (ESCs). These 
cells basically recapitulate in vitro the developmental 
process and ESCs in particular are indeed a continuous 
source of terminally differentiated post-mitotic cells that 
can be currently easily studied. The isolation and the 
use of human ESCs, although obtained from surplus of 
in vitro fertilization procedures, opened a serious and 
profound ethical issue. The great revolution came in 2006 
when Shinya Yamanaka proposed a complex protocol 
designed to change cellular fate by forcing transcription 
factor expression[1]. With this procedure, a murine 
follow embryonic development (P. Dell’Era, unpublished 
results). 
Since their isolation, human ESCs have shown 
different culturing needs from the murine counterpart, 
and their behavior revealed also minor differentiation 
plasticity. Cardiac differentiation is the most glaring 
example of this statement. The spontaneous 3D 
differentiation of mESC leads to the easy appearance 
of spontaneous beating foci in all the considered 
EBs, while in the case of both hESC and hiPSC, only 
a modest proportion of EBs contains contracting 
cells. This occurrence leads to the setup of different 
methods aimed to increase cardiac differentiation 
during in vitro development of pluripotent stem cells. 
While some of these procedures retain an initial 
3D EB formation, others start from a confluent 2D 
monolayer. 
Differentiation protocols
During gastrulation, cardiomyocytes emerge from 
mesodermal tissue, in particular from the anterior 
region of the primitive streak. Bone morphogenetic 
protein produced by the adjacent endoderm induces 
the cardiomyocyte fate, whereas WNT-mediated 
signals from the underlying neural tube and notochord 
suppress cardiomyocyte specification. Therefore the 
timed addition of inducers and/or inhibitors of the cited 
pathways would guide PSC differentiation toward: 
mesoderm, cardiomyogenic mesoderm, cardiac 
precursors, and cardiomyocytes. This is conceptually 
the summary of several protocols. At variance the 
required instructive signals can be provided by a 
visceral endoderm-like cell line that can be used as a 
feeder layer during the differentiation process[7].
Within these years, several efforts have been 
made to identify a protocol that would give rise to high 
percentage of cardiomyocytes following differentiation 
of either hESC or hiPSC. All the attempts lead to the 
creation of several tools such as defined cultivation 
media that, avoiding animal components, will facilitate 
therapeutic use of pluripotent stem cells; recombinant 
single protein matrices such as vitronectin or laminin; 
aggregation plates to standardize the production of 
EBs; and the more recent commercial cardiomyocyte 
differentiation media (StemRD and Life Technologies). 
The main differentiation protocols that have been used 
over the years are outlined in Table 1. 
We tested several of these procedures using iPSC 
derived from patients’ fibroblasts and adapted to 
grow on Matrigel-coated dishes; in our experience, 
we observed beating areas only when cells were 
treated with modulators of the Wnt pathway, while 
the general TNNT2 expression was achieved in 
most protocols (Figure 1B). Of particular interest for 
therapeutic purposes the recent setup by Burridge 
et al[8] that employs a chemically defined medium 
consisting of just three components on a dish covered 
by synthetic biological matrices. Indeed, using this 
protocol we strongly increased the number of beating 
cells in our culture up to 50%, but the best result, 
around 70%, was recently obtained using the PSC 
Cardiomyocyte Differentiation Kit (Life Technologies). 
From spontaneously contractile 
cells to mature carDiomyocytes
In early development, the primitive heart tube is 
composed by small myocytes without distinct region 
of cells conducting and coordinating the stimulus. The 
contractile impulse begins with the primary pacemaker 
area in the primitive atrium that will later evolve in 
the sinoatrial node, where the fast beating pacemaker 
myocytes will reside. As development proceeds, also 
the conductive system will differentiate, generating 
CMs in anatomical different regions that will become 
the atrio-ventricular (AV) node, the AV bundles, and 
Purkinje fibers. Each of these CM subtype has its own 
electrical properties such as the presence and the form 
of the action potential (AP), the contraction rate, and 
the presence of specific currents that can be measured 
electrophysiologically.
However, CMs differentiated in vitro vary considerably 
from cells isolated from a mature human heart, because 
of the absence of humoral factors and organized 
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Figure 1  Cardiomyocyte at day 16 post differentiation. A: Microscopical view of beating areas; B: Expression of cardiac troponin T (green), nuclei (DAPI) in blue; C: 
Cardiomyocyte sarcomeric structures evidenced by cardiac troponin T staining (green), nuclei (DAPI) in blue.
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CMs, but expression levels of M-band-specific genes 
remained lower in comparison with those in the adult 
heart[14].
Also a different gene expression accompanies 
these changes: late-stage CMs show increased levels 
of structural filaments MYH6 and MYH7, and of other 
specific molecules such as connexin 43, hyperpolarization 
activated cyclic nucleotide-gated potassium channel 4, 
and sarco(endo)plasmic reticulum Ca2+ ATPase[14-16]. 
Finally, the electrophysiological profile of late-stage 
hESC-CMs show a significantly enhanced AP upstroke 
and a hyperpolarized maximum diastolic potential, and 
during maturation no differences were observed for 
AP duration (APD) to 50% or 90% (APD50, APD90) of 
repolarization[15].
It must be noted that, while at early differentiation 
stages there are unspecified CMs that co-express 
different CM-subtype markers at later stages, around 
dd30, CMs acquire a more specific phenotype, 
expressing ventricular-, atrial-, and nodal-markers[8]. 
The relative proportion of the three CM subtypes 
varies among the differentiation protocols that have 
been used, and can be additionally modulated by 
supplementing chemicals, microRNAs, or biological 
molecules to the culture[17].
carDiac Disease moDeling 
Despite all the discussed limitations, hPSC differ-
entiation remains a powerful method to model in vitro 
genetic cardiac diseases, because of the capacity of 
these cells to give rise to terminally differentiated 
stable cardiac cells. The cardiac pathologies that 
have been modeled so far using hiPSC include some 
cardiomyopathies and arrhythmias, whose implicated 
mechanical and electrical stress. In general, many of 
the features of hPSC-CMs are reminiscent of normal 
fetal cells. hPSC-CMs are spontaneously beating cells co-
expressing atrial-, ventricular-, and nodal- markers, with 
unorganized sarcomeres, immature mitochondria, and 
an expression profile different from adult CMs[9]. Our data 
indicate that, after 16 d of in vitro differentiation, iPSC-
derived CMs start to segregate in the various subtypes, 
showing pronounced sarcomeric structures that reveal a 
certain degree of maturation (Figure 1C).
The CMs that arise during early hESC or hiPSC in 
vitro differentiation exhibit spontaneous AP, with a 
relatively depolarized resting membrane potential, 
probably due to the temporary absence of the inward 
rectifier potassium current (IK1)[10].  
The expression of the ion channels and, consequently, 
the ionic currents will undergo developmental maturation 
over time, as assessed by modifications in current 
density and property[10]. hPSC-CMs immaturity is also 
reflected in their excitation-contraction machinery, 
lacking clear T-tubuli, disorganized sarcomeric striations, 
and immature Ca2+ handling[11-13]. Unlike primary CMs 
that tend to undergo apoptosis or dedifferentiate, CMs 
derived from hPSC develop and maintain a functional 
phenotype in long-term culture[14]. After surviving for 80 d, 
late-stage hESC-CMs show pronounced multinucleation 
that is accompanied by an increase in cellular perimeter, 
and area[15]. Ultrastructural studies demonstrated 
that the sarcomere of hiPSC-CMs continue to mature 
through a 1-year culture[16]. Young hiPSC-CMs contained 
a low number of unaligned myofibrils and immature 
high-density Z-bands. Within 6 mo the myofibrils 
became more tightly packed and formed parallel arrays 
accompanied by the appearance of mature Z-, A-, H-, 
and I-bands. M-bands were finally detected in 360-d-old 
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Table 1  From pluripotent stem cells to cardiomyocyte: Details of main cardiac differentiation protocols
PSC type Differentiation Pre-treatment Cardiac differentiation treatment % Beating cells % cTNT + cells Ref.
h-iPSC h-ESC 2D 3D Others ROCK-I GSK-I BMP4 Activin A Wnt-I FGF2 Others
X END2 AA < 40% n.a. [83]
X X X Specific 
serum
5%-10% hiPSC n.a. [20]
10%-25% hESC
X X X X X n.a. > 80% hiPSC [84]
60%-80% hESC
X X X X AA n.a. 50%-70% [85]
X X X p38-
MAPK-I
> 23% hiPSC n.a. [86]
50% hESC
X X Sandwich X X X X n.a. 98% [87]
X X X X X X X X AA n.a. 80% [88]
X X X END-2-CM n.a. < 10% [89]
X X X X X X MEF-CM n.a. < 60%
X X X X Tricho-
statin A
< 50% < 10% [90]
X X X X X X X X VEGF < 50% hiPSC n.a. [91]
< 40% hESC 95% hESC
X X X X Albumin, AA n.a. 90% [8]
X X X X X X VEGF < 40% < 20% [92]
X X X X X X Blebbistatin 100% 90% [93]
iPSC: Induced pluripotent stem cell; ESC: Embryonic stem cell; n.a.: Not available.
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genes are listed in Table 2. 
hiPSC modeled cardiomyopathies
Familial hypertrophic cardiomyopathy: Hyper-
trophic cardiomyopathy (HCM) is a heterogeneous 
monogenic heart disease in which a portion of the 
myocardium is heavily hypertrophic. It is caused 
by more than 1400 mutations in at least 11 genes 
that encode thick and thin contractile myofilaments 
of the sarcomere or the adjacent Z-disc[18]. HCM 
patients display abnormal thickening of the left 
ventricular myocardium in the absence of increased 
hemodynamic burden. Most people with familial HCM 
are symptom-free or have only mild symptoms, but 
their risk for clinical complications such as progressive 
heart failure, arrhythmia, and sudden cardiac death is 
strongly increased. 
Efforts to elucidate the mechanisms underlying 
development of HCM have lead to the generation 
of patient-specific hiPSC-CMs that recapitulate in 
vitro a number of disease characteristics including 
cellular hypertrophy, and contractile arrhythmia[19]. 
hiPSC were generated from a family cohort carrying a 
hereditary HCM missense mutation (Arg663His) in the 
MYH7 gene, and CMs were generated using the 3D 
spontaneous differentiation protocol[20]. Mutant hiPSC-
CMs demonstrated not only cellular enlargement 
and multinucleation, but also other hallmarks of 
HCM including expression of atrial natriuretic factor, 
elevation of β-myosin/α-myosin ratio, calcineurin 
activation, and nuclear translocation of nuclear factor 
of activated T cells[19]. Using this model the authors 
were able to show that irregular Ca2+ transients and 
elevation of diastolic intracellular calcium [Ca2+]i 
precedes the presentation of other phenotypic 
abnormalities, strongly implicating dysregulation 
of Ca2+ cycling in the pathogenesis of the disease. 
Pharmaceutical drug screening of mutant hiPSC-
CMs further supported elevated [Ca2+]i as a central 
mechanism for arrhythmia development. Indeed, 
only pharmaceutical blockade of Ca2+ and Na+ entry 
mitigated contractile arrhythmia in HCM-CMs[19].
Dilated cardiomyopathy: Dilated cardiomyopathy 
(DCM) represents the final common morphological 
and functional consequence of various pathological 
conditions in which a combination of myocyte injury 
and necrosis associated with tissue fibrosis results in 
impaired heart mechanical function. Nevertheless, 
primary familial forms of DCM represent a genetic 
condition in which the pathological involvement is 
predominantly limited to the myocardium. The main 
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Table 2  Inherited cardiac diseases modeled using Induced pluripotent stem cell
Cardiac 
disease
Gene Protein/current Chr Mutation Differentiation method Cardiomyocyte 
subtype
Maturation 
days
Ref.
HCM MYH7 Myosin heavy 
chain β  
14q12 R663H 3D spontaneous [19]
DCM LMNA Lamin A 1q22 R225X END-2 co-culture V- and A-like 20 [25]
GCCA insertion 
TNNT2 Troponin T type 2 1q32 R173W 3D, activin, BMP4, DKK1, FGF2, VEGF V-, A-, and N-like > 30 [27]
DES Desmin 2q35 A285V END co-culture n.d. > 14 [26]
BTHS TAZ Tafazzin Xq28 517delG 2D, activin, BMP4 n.d. > 12 [30]
c.328T>C 
LQT1 KCNQ1 Kv7.1/I(Ks) 11p15 R190Q 3D spontaneous V-, A-, and N-like 20-30 [36]
LQT2 KCNH2 hERG/I(Kr) 7q36 R176W 3D spontaneous V- and A-like n.d. [42]
A561T V-, A-, and N-like 25-30 [38]
A561V V- and A-like 21 [45]
A614V V-, A-, and N-like > 30 [37]
N996I n.d. 20-60 [43]
LQT3 SCN5A Nav1.5 /I(Na) 3p21 F1473C 3D, activin, BMP4, Wnt-I, FGF2 V- and A-like 25-45 [50]
V1763M 3D spontaneous V-, A-, and N-like > 28 [51]
V240M, R535Q END-2 co-culture V-, A-, and N-like 20-30 [52]
LQT8 CACNA1C CaV1.2/I(Ca) 12p13 G1216A 3D + Wnt3a V-, A-, and N-like > 37 [55]
CPVT RYR2 Ryanodine receptor 
2/I(Ca)
1q43 F2483I END-2 co-culture V-, A-, and N-like 20-30 [61]
P2328S END-2 co-culture Mostly V-like n.d. [62]
S406L 3D spontaneous V-, A-, and N-like > 70 [64]
M4109R 3D spontaneous V-, A-, and N-like > 30 [65]
E2311D 3D spontaneous V/A- and N-like > 30 [66]
CASQ2 Calsequestrin 1p13 D307H 3D spontaneous n.d. 25-43 [67]
ARVC PKP2 Plakophilin-2 12p11 L614P 3D spontaneous V-, A-, and N-like > 28 [72]
A324fs335X 3D spontaneous n.d. > 30 [73]
T50SfsX110
Criptic splicing 3D spontaneous n.d. > 60 [74]
c.2013delC 
HCM: Hypertrophic cardiomyopathy; DCM: Dilated cardiomyopathy; BTHS: Barth syndrome; LQT: Long-QT; CPVT: Catecholaminergic polymorphic 
ventricular tachycardia; ARVC: Arrhythmogenic right ventricular cardiomyopathy; n.d.: Not defined.
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hallmark of primary DCM is the presence of a left 
or biventricular dilatation with severely impaired 
systolic function in the absence of abnormal loading 
conditions or ischemic heart disease sufficient to 
cause global systolic impairment[21]. Point mutations 
in 31 autosomal and 2 X-linked genes have been 
implicated in causing familial DCM (FDC) but account 
for only 30% to 35% of genetic causes[22]. One of the 
more common genes identified in FDC is LMNA, which 
codes for lamin A/C proteins, intermediate filament 
proteins of the nuclear lamina[23].
Several animal models of LMNA mutations 
have been generated to provide initial insights into 
the pathophysiology of lamin A/C-related DCM[24]. 
Nevertheless the mechanism that links LMNA 
mutations with DCM remains uncertain.
Two different LMNA mutations have been modeled 
using hiPSC-CMs: an autosomal dominant non-sense 
mutation (R225X) in exon 4 of the lamin A/C and a 
GCCA insertion at base 50 in LMNA that creates a 
frameshift and premature stop codon, hence causing 
lamin A/C haploinsufficiency. LMNAR225X/WT and 
LMNAFrameshift/WT hiPSC-CMs showed normal phenotypes 
and basal electrophysiological properties as control 
hiPSC-CMs. However, when these CMs were subjected 
to electrical stimulation as in the cardiac environment, 
they exhibited typical nuclear abnormalities together 
with increased apoptosis[25]. These two properties 
were replicated in vitro by shRNA knockdown of 
LMNA in control hiPSC-CMs, that was ineffective 
when the MEK1/ERK1/2 pathway was blocked 
pharmacologically[25], thus identifying this pathway as 
a potential therapeutic target in LMNA-related DCM. 
The same group also modeled a pathogenic 
phenotype of DCM due to a novel A285V Desmin (DES) 
mutation identified by whole exome sequencing (WES) 
using the hiPSC-CM system[26]. Characterization of 
hiPSC-CMs carrying A285V-DES mutation revealed a 
poor co-localization of DES with several cytoskeletal 
proteins, including cardiac troponin-T, α-actinin and 
F-actin, and diffuse isolated aggregations of DES-
positive protein[26]. The electrophysiological analysis 
revealed that A285V-DES CMs exhibit significant 
functional abnormalities compared with the control-
CMs as demonstrated by the diminished maximum 
rate of calcium ion re-uptake, slower spontaneous 
beating rate and failure to respond to the inotropic 
stress induced by isoproterenol[26]. When control-iPSC-
CMs were transduced with a lentivirus carrying the 
A285V-DES mutation, the resulting CMs simulated the 
phenotypes of DES-DCM-CMs, thus confirming the idea 
that abnormal DES-positive protein aggregates due 
to DES mutation can cause structural and functional 
abnormalities in cardiomyocytes. The relevance of 
this study is the demonstration that patient-specific 
hiPSC-CMs can be used to provide confirmation of a 
suspected genetic basis for DCM identified by WES.
Lastly, cardiomyocytes derived from patients in a 
DCM family carrying a point mutation (R173W) in the 
gene encoding sarcomeric protein cardiac troponin 
T were analyzed[27]. Compared to healthy individuals 
in the same family cohort, CMs from DCM patients 
exhibited altered regulation of Ca2+, decreased 
contractility, and abnormal distribution of sarcomeric 
β-actinin. When stimulated with a β-adrenergic 
agonist, CMs showed characteristics of cellular 
stress such as reduced beating rates, compromised 
contraction, and abnormal sarcomeric β-actinin 
distribution. Treatment with β-adrenergic blockers 
or overexpression of sarcoplasmic reticulum Ca2+ 
adenosine triphosphatase rescued the pathological 
phenotype[27].
Barth syndrome: Barth syndrome (BTHS) is a rare, 
metabolic, and neuromuscular genetic disorder that 
occurs exclusively in males. Clinical features include 
variable combinations of pathologies including DCM, 
HCM, endocardial fibroelastosis, left ventricular 
non-compaction, ventricular arrhythmia, sudden 
cardiac death[28]. The gene responsible for the 
disorder, tafazzin (TAZ), has recently identified: 
it is located on the long arm of chromosome X at 
Xq28, and encodes an acyltransferase that catalyzes 
the acylation of cardiolipin, the major phospholipid 
of the mitochondrial inner membrane[28,29]. So far, 
more than 120 mutations have been described, but 
no correlation with specific phenotype has been 
observed[28].  
hiPSCs from two unrelated individuals with BTHS 
were generated, BTH-H and BTH-C, carrying TAZ 
frameshift (c.517delG) and missense (c.328T > 
C) mutations, respectively. CMs were generated 
by treating a cell monolayer with inducers and 
sorted for the surface marker vascular cell adhesion 
molecule-1 to obtain preparations highly enriched 
in CMs. Purified CMs were analyzed morphologically 
to evaluate sarcomere organization, and to assess 
mitochondrial functionality. CMs were then seeded 
onto thin elastomers with patterned lines of 
fibronectin, obtaining self-organized anisotropic 
myocardial tissues to study contractility properties[30]. 
TAZ deficiency in BTHS-CMs impairs mitochondrial 
functionality as well as sarcomere assembly, generate 
contractile stress, and markedly increase reactive 
oxygen species (ROS) production. When linoleic acid 
(LA), an essential unsaturated fatty acid precursor 
of mature cardiolipin, was added to CM culture, the 
metabolic phenotype was corrected, the sarcomere 
organization and contractile defects were mitigated, 
and ROS production was strongly reduced[30].
Using the hiPSC-derived model the authors 
showed that suppression of ROS, not only by LA 
but also by mitoTEMPO, normalized the metabolic, 
sarcomerogenesis and contractile phenotypes of 
BTHS- CMs, thus setting the basis for an effective 
pharmacological therapy of BTHS patients[30]. 
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hiPSC modeled arrhythmias
Long-QT syndromes: Long-QT syndromes (LQTS) 
are a group of heritable, usually autosomal dominant 
disorders with a estimated prevalence of 1:2500, 
characterized by an abnormally delayed or prolonged 
ventricular repolarization phase (prolongation of the 
QT interval on an electrocardiogram) and a propensity 
toward polymorphic ventricular tachycardia (often 
termed Torsades de pointes, TdP), syncope and 
sudden cardiac death in young patients[31]. Clinically 
LQTS present a broad range of phenotypes even 
among family members with identical mutations, 
possibly as a result of genetic modifiers[32]. To date, 
LQTS have been associated with over 500 different 
mutations in at least 13 genes encoding cardiac 
ion channel proteins, but the most prevalent forms 
are LQT1 and LQT2 caused by potassium channel 
mutations with a percentage of genotyped cases of > 
50% and 30%-40%, respectively, and LQT3 caused 
by a sodium channel mutation that accounts for 
10%-15%[31]. 
LQT1 patients carry mutations in the KCNQ1 gene 
(also known as KVLQT1 or Kv7.1), which encodes the 
pore-forming α-subunits of the channels generating 
IKs, an adrenergic-sensitive, slow outward potassium 
current, while LQT2 implicates hERG protein (encoded 
by KCNH2 gene), which constitutes pore-forming 
α subunit of the rapidly-activating delayed rectifier 
potassium current (IKr)[33]. LQT3 is instead associated 
with gain-of-function mutations of the SCN5A gene, 
which encodes the α-subunit of the Na+ ion channel 
NaV1.5[34], while loss-of-function mutations in the same 
gene are associated with several other genetically 
heterogeneous disorders including Brugada syndrome, 
cardiac conduction disease, sick sinus syndrome sudden 
infant death syndrome and others[35]. 
LQT1 was the first cardiac disease modeled using 
hiPSC and since then several hiPSC-CMs from patients 
carrying mutations in LQTS-associated channels 
have been considered[36-42]. Indeed, patient-specific 
hiPSC-CMs represent a platform to investigate the 
functionality of ion channel mutations expressed in 
their complex genetic backgrounds and may provide 
unique insight into therapeutic approaches for disease 
management[43].
LQT1: A family affected by LQT1 was screened and 
an autosomal dominant missense mutation R190Q 
in the KCNQ1 gene was identified[36]. hiPSC from 
two family members and two healthy controls were 
generated by retroviral vectors encoding the human 
transcription factors OCT3/4, SOX2, KLF4, and c-MYC 
(hOSKM). Using a 3D differentiation protocol, these 
cells were then differentiated into CMs. Spontaneously 
beating cells dissociated from LQT1 and control 
explants responded to pacing and generated three 
distinct types of APs, designated as “ventricular (V)”, 
“atrial (A)”, and “nodal (N)” on the basis of their 
similarity to the APs of human fetal heart CMs[36]. 
Several disease-specific abnormalities were observed 
in LQT1-CMs: the duration and the rate adaptation 
of the AP, a 70%-80% reduction in IKs, as well as 
vulnerability to catecholaminergic stress[36]. R190Q– 
KCNQ1 is a dominant mutation and indeed in hiPSC-
CMs the mutated protein was absent on cell surface, 
but still retained in the endoplasmic reticulum. Similar 
results were obtained by expressing the wild type 
and the mutated protein in cardiomyoblast H9c2 
cell line[36]. Furthermore, electrophysiological studies 
confirmed the protective effect of β-blockade in the 
abnormal response to catecholamine stimulation, thus 
confirming the efficacy of the therapeutic approach 
for LQT1 patients[36].
LQT2: The voltage-gated inwardly rectifying potassium 
channel that comprise KCNH2-encoded protein is 
composed of homo- or heterotetrameric complexes 
of pore-forming α subunits, like hERG, that associate 
with modulating β subunits. hERG consists of six 
transmembrane α helices, a pore helix, and N- and 
C-termini cytoplasmically located. The channel mediates 
the rapidly activating component of the IKr in heart[44]. A 
large number of natural variants have been described, 
most of them in association with LQT2 syndrome (see 
http://www.uniprot.org/uniprot/Q12809).
A panel of control and LQT2-related hPSC were 
generated and characterized by several laboratories. 
hiPSC-CMs showing five different hERG mutations 
in genetically unrelated backgrounds were intensely 
characterized: R176W[42], A561T[38] and A561[45], 
A614V[37], and N996I[46]. The aminoacids 176 and 
996 reside in the N- and C-terminus cytoplasmic 
domains respectively, while the position 561 is in 
a transmembrane region of the protein, and the 
aminoacid 614 is located in the pore-forming segment. 
Heterozygous KCNH2 mutations exert a dominant-
negative effect on wild-type (WT) hERG channels 
associated IKr, by impairing trafficking pathways or 
altering channel kinetics of the resulting co-assembled 
hERG heterotetramers[31,47]. Due to this behavior, it 
is possible to transfer them in a WT environment to 
verify their biological consequences in an unrelated 
genetic background. 
The reprogramming and the following differentiation 
process were similar for all the laboratories: most of 
them used a retroviral transduction system, except for 
Mehta et al[45] that choose a viral-free episomal non-
integrating approach, but the following differentiation 
involving EB formation and spontaneous differentiation 
was identical for all of them. 
It must be pointed out that LQT2 is a disorder with 
incomplete penetrance where genetic background 
variations can confound disease traits. For this reason, 
the KCNH2 N996I mutation was deeply analyzed in 
(1) hiPSC-CMs from LQT2 patient; (2) hiPSC-CMs 
from LQT2 patient, previously corrected to wild-type 
using an homologous recombination system; and (3) 
NKX2.5eGFP/w hESC-CMs where the N996I-KCNH2 
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mutation was introduced using the same approach as 
before[46].
Several observations were commonly reported to 
all LQT2-CMs: intracellular patch clamp recording of 
APD or extracellular measurement of field potential 
duration (FPD) using multi electrode array (MEA) 
showed prolonged intervals for both A-like and V-like 
cells[37,38,42,45,46]. A summary of AP characteristic 
parameters measured by several authors in iPSC- 
or ESC-derived CMs is reported in Hoekstra et al[48]. 
Nevertheless, the AP increase was more restricted 
when isogenic cell lines were compared[46], thus 
suggesting that a different genetic background can 
indeed over-estimate the differences between a 
control versus diseased CMs.
AP was modulated in LQT2-CMs by several drugs: 
pinacidil, a KATP-channel opener, significantly shortens 
APD90, while Na-channel blocker, ranolazine, was 
ineffective[37]; K channel enhancers, nicorandil and 
PD118057, caused AP shortening and in some cases 
could abolish early afterdepolarization (EAD)[38]. 
In most of the papers some arrhythmogenicity 
of LQT2-CMs was reported, as evidenced by EAD 
events during spontaneous recordings[37,42,45] or 
when challenged with the clinically used stressor, 
isoprenaline[38].
As expected, the measurement of IKr, determined 
by adding the specific E4031 inhibitor, showed a 
reduction in LQT2-derived versus control CMs[37,42,45,46].
Definitively, the genetic correction of the N996I-
KCNH2 mutation associated with LQT2 restores IKr 
density and normalizes APD in patient-specific LQT2-
CMs, while the introduction of the same mutation 
in hESC-CMs reduced IKr and prolonged the AP 
duration[46]. In addition, the molecular defects of 
hERG A561V and N996I mutants have been analyzed. 
In the NKX2.5-eGFP+ hESC-N996I cells, as well as in 
LQT2-N996I CMs, a trafficking defect was identified. 
Indeed, the 155-kDa protein band, representing the 
form transported to the cell membrane through the 
Golgi, was reduced by two-fold compared to the WT 
protein, while the 135-kDa band, which corresponds 
to the protein located in the ER, was unaffected[46]. 
Similarly, hERG mutation A561V causes a reduced 
membrane localization of glycosylated/mature 
protein[45]. Treatment of LQT2-A561V CMs with the 
calpain and proteasome inhibitor ALLN, not only 
increased membrane localization of mature hERG but 
also reduced repolarization, increased IKr and reduced 
arrhythmogenic events, thus suggesting a new 
therapeutic approach to treat LQT2 patients[45].
LQT3: The α-subunit of the Na(v)1.5 cardiac sodium 
channel, encoded by SCN5A gene is composed by 
intracellular N- and C- terminus, and four homologous 
domains, attached one another by cytoplasmic 
linkers, forming a pore that conducts Na+ ions across 
membrane[49]. In LQT3, the gain-of-function SCN5A-
mutations cause an increased persistent Na+ influx 
during depolarization that results in an enhanced late 
or persistent sodium current due to defective open-
state inactivation of the channel[35]. Four different 
SCN5A alterations have been modeled using hiPSC 
cellular system: a de novo heterozygous missense 
mutation F1473C associated with a polymorphism 
(K897T) in KCNH2, identified in a newborn patient 
with extreme prolonged QT interval[50]. The second 
SCN5A modification was again a de novo heterozygous 
missense V1763M mutation, found in a Chinese 
girl[51], and the last two V240M and R535Q alterations 
were from two LQT3-diagnosed patients[52]. The 
F1473C mutation occurs in the channel inactivation 
gate of SCN5A while V240M and V1763M reside in 
transmembrane segments, and R535Q mutation 
occurs in the first cytoplasmic linker[53].
In the first paper a lentiviral transduction of 
OSKM was used to reprogram fibroblasts, and a 
complex protocol rich in developmental modulators 
was used to achieve CMs differentiation[50]. Ma et 
al[51] used instead an mRNA-based non viral non 
integrating reprogramming approach, followed by 
the spontaneous EB-based CM differentiation. Finally 
Fatima et al[52] used the classical retroviral infection, 
followed by a differentiation protocol guided by END-2 
co-culture.
The data of hiPSC-CMs from the newborn and 
from the Chinese girl were compared with those 
obtained from hiPSC-CMs of healthy parents and 
of a healthy sister respectively that, because of 
the common genetic background with the patients, 
strengthened the obtained results[50,51]. 
Terrenoire et al[50] reported a mutation-dependent 
increase in INaL, a right-shifted steady-state channel 
availability, and faster recovery from inactivation in all 
clones from the proband and none of the parents’ clones. 
By using the hiPSC-CM system, the authors easily showed 
that the KCNH2 heterozygous polymorphism T897 and 
K897, derived from homozygous parents, had no impact 
on electrophysiological pathology of the proband[50]. 
Furthermore, the system allowed the pharmacological 
evaluation of the current patient’s therapy, not so 
effective in controlling episodes of arrhythmia. Indeed, 
a more effective therapy has been identified as a result 
of the proposed study[50].
Ma et al[51] observed significantly prolonged APD 
in patient-derived V-like CMs compared with control 
cells, while Fatima et al[52], showed a tendency to 
prolonged APD not statistically significant. Relevant 
to this point Terrenoire et al[50], comment that the 
relatively depolarized diastolic membrane potentials at 
this embryonic developmental stage inactivate sodium 
channels and consequently minimize contributions of 
sodium channel activity to AP[53]. Relatively to sodium 
current Ma et al[51] found that TTX-sensitive INaL was 
significantly larger in patient-derived hiPSC-CMs 
compared with control hiPSC-CMs[51], while Fatima et al[52] 
336 March 26, 2015|Volume 7|Issue 2|WJSC|www.wjgnet.com
Dell’Era P et al . iPSC-derived diseased cardiomyocytes
showed that time-to-peak for sodium current and time 
to 90% of inactivation of the Nav1.5 were significantly 
longer in the LQT3-CM[52]. In agreement with previous 
findings[50], mexiletine reduced the late Na+ current and 
shortened the APD in patient hiPSC-CMs[51].
LQT8/Timothy syndrome: Timothy syndrome (TS) 
is a multi-system disorder characterized by cardiac, 
hand, facial and neurodevelopmental features that 
include QT prolongation, webbed fingers and toes, 
flattened nasal bridge, low-set ears, small upper jaw, 
thin upper lip, and characteristic features of autism or 
autistic spectrum disorders (see www.orpha.net).
TS is caused by mutations in the CACNA1C gene 
and is inherited as autosomal dominant trait. The 
gene codifies for CaV1.2 channel, the main L-type 
channel in the mammalian heart that is essential 
for generating the cardiac action potential and for 
excitation contraction coupling[54].
To date, just one paper reported the modeling of 
this syndrome using hiPSC: 16 iPSC lines from two 
TS patients, and 10 control lines from two unrelated 
individuals were generated using the classic retroviruses, 
and CMs were then obtained spontaneously from EBs[55].
A prolonged AP was observed in TS-V-like CMs, 
while no differences were observed in A-like and 
N-like cells[55]. The L-type Ca2+ channel current had 
significantly reduced voltage-dependent inactivation 
in TS-CMs compared to control cells[55]. In addition, 
the TS-CMs exhibited a large number of depolarizing 
events that failed to trigger a full AP, similar to delayed 
afterdepolarizations (DADs) that arise after ectopic 
release of Ca2+ from the sarcoplasmic reticulum and 
which are associated with cardiac arrhythmias[55]. 
Moreover, the Ca2+ elevations in spontaneously 
contracting TS-CMs were more prolonged and 
more irregular than those of control CMs[55]. Finally, 
roscovitine rescued the electrophysiological properties 
of TS- CMs by increasing CaV1.2 voltage-dependent 
inactivation, reducing the APD, and decreasing the 
frequency of abnormal depolarizing events[55].
Catecholaminergic polymorphic ventricular 
tachycardia: Another inherited cardiac disorder that 
was studied using hiPSC-CMs is catecholaminergic 
polymorphic ventricular tachycardia (CPVT) that 
is characterized by emotional and physical stress-
induced ventricular tachyarrhythmia, syncope and 
sudden cardiac death in children and young adults. 
Two type of CPVT have been described: the autosomal 
dominant form (CPVT1) linked to mutations in the 
cardiac ryanodine receptor type 2 gene (RYR2) and 
a rare autosomal recessive form (CPVT2) caused by 
mutations in the calsequestrin-2 gene (CASQ2)[56].
RYR2 gene encode for the principal Ca2+-releasing 
channel expressed in the membrane of the sarcoplasmic 
reticulum (SR). Studies based on in vitro expression 
of mutant RYR2 in heterologous cell systems and 
transgenic mice carrying specific RYR2 mutations 
suggested that arrhythmias in CPVT1 are due 
to the diastolic Ca2+ leak from the SR following 
catecholaminergic stimulation[57]. This leakage may 
lead to develop DADs through activation of the 
membrane Na+/Ca2+ exchanger, which can eventually 
result in triggered activity[58].
The CASQ2 gene encodes for a high-capacity, 
low affinity Ca2+ binding glycoprotein located inside 
the SR and involve in excitation-contraction coupling 
process[59]. The functional alterations in intracellular 
Ca2+ handling resulting from the mutated CASQ2 
gene may cause DADs[60]. In 2011, Fatima and his 
group described the hiPSC generation from a patient 
with CPVT1 carrying the mutation F2483I in RYR2 
gene[61]. The authors differentiated hiPSC-CMs from 
fibroblasts of the CPVT patient and after 20-30 d of 
culture the cells were electrophysiologically analyzed. 
Frequent DADs and arrhythmias in CPVT-CMs exposed 
to adrenergic agonists were consistently observed. 
Furthermore, abnormal sensitivity to phosphorylation 
and cAMP-mediated regulation, together with the 
tendency for ICa-triggered Ca2+ release to continue 
following repolarization have been found[61]. These first 
results using hiPSCs-based cardiac model validated the 
earlier hypothesis obtained only with animal models. 
Different groups have obtained similar results: Kujala 
has demonstrated that in addition to DADs, CPVT-
CMs with P2328S RYR2 mutation displayed also EADs 
which may be involved in cardiac arrhythmogenesis 
of their patients[62]. Zhang reported specific analyses 
on calcium current (ICa) and Na+-Ca2+ exchanger 
current (INCX): in this case RyR2 F2483I mutant CMs 
have aberrant unitary Ca2+ signaling, smaller INCX 
reflecting smaller Ca2+-stores, higher ICa-gated Ca2+-
release gains, and sensitized adrenergic regulation, 
consistent with functionally altered Ca2+-release profile 
of CPVT syndrome[63]. Jung also reported the hiPSC 
generation of a 24-year-old woman with a diagnosis 
of familial CPVT1 with S406L missense mutation 
in the RYR2 gene[64]. In addition to presenting the 
electrophysiological properties of CPVT-CMs, the 
rescue capacity of dantrolene, which is believed to 
stabilize skeletal and cardiac RYRs by binding to a 
N-terminal sequence, is analyzed. Treatment with 
dantrolene restored normal Ca2+ spark properties in 
CPVT-CMs under basal conditions and corrected S406L-
RYR2 hyperactivity induced by adrenergic stimulation, 
with minimal effects in control cells; moreover, the 
same drug completely abolished DADs and triggered 
arrhythmias[64].
Two more studies evaluated the effects of different 
drugs onto CPVT-CMs: Itzhaki reported the positive 
effects of flecainide, an antiarrhythmic agent, and 
thapsigargin, a β-blocker on CMs carrying the RYR2 
M4109R mutation[65], while Di Pasquale et al[66] reported 
the rescue of the arrhythmic phenotype induced by 
catecholaminergic stress by KN-93, an antiarrhythmic 
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drug that inhibits Ca2+/calmodulin-dependent serine–
threonine protein kinase Ⅱ on CMs carrying the RYR2 
E2311D mutation. 
An additional study focused on the autosomal 
recessive form of the disease caused by the missense 
mutation D307H in CASQ2[67]. In agreement with 
previous observations, isoproterenol stimulation 
caused DADs, oscillatory arrhythmic prepotentials 
and after-contractions, and diastolic intracellular 
calcium rising in CASQ2-derived CPVT model[67]. Most 
importantly, electron microscopy showed that CMs 
derived from CPVT patients present an immature 
morphology with less-organized myofibrils, enlarged 
SR cisternae, and reduced number of caveolae[67]. 
These data confirm previous findings derived from 
knock-out and knock-in Casq2 mice that showed 
ultrastructural abnormalities in the SR[68,69].
Arrhythmogenic right ventricular cardiomyopathy: 
Arrhythmogenic right ventricular cardiomyopathy (ARVC) 
is a heritable primary cardiac disease characterized by 
the replacement of CMs with fatty or fibrofatty tissue[70]. 
ARVD has an autosomal dominant trait with reduced 
penetrance; approximately 40%-50% of ARVD patients 
have a mutation identified in one of several genes 
encoding components of the desmosome, which can 
help confirm a diagnosis of ARVD[71].
Also ARVC has been modeled using hiPSC by 
three independent groups starting from skin biopsies 
of five patients: retroviruses were used to transduce 
patient’s-derived fibroblasts and CMs were differ-
entiated with the spontaneous 3D differentiation 
protocol[72-74]. The five patients carried different 
alterations in Plakophilin-2 gene (PKP2), a structural 
component of desmosome[75]: a heterozygous L614P 
mutation[72]; a heterozygous insertion resulting in 
a frame shift from amino acid 324 to a stop codon 
in position 335 (A324fs335X) and a heterozygous 
deletion resulting in replacement of threonine by 
serine in position 50 and in a frame shift leading to a 
stop codon in position 110 (p.T50SfsX110)[73]; and, 
finally, a homozygous mutation that causes cryptic 
splicing with a 7-nucleotide deletion in exon 12, 
leading to frame-shift of the carboxy-terminal amino 
acids, whose results were further confirmed with cells 
carrying a heterozygous c.2013delC in exon 10 of 
PKP2[74].
Common observations of ARVC-CMs carrying 
the heterozygous conditions reported specific down-
regulation of PKP2 and its interactor plakoglobin 
both at mRNA and at protein level[72,73]. Transmission 
electron microscopy (TEM) analysis displayed larger 
ARVC-CMs with less organized, thicker and more 
pleomorphic Z-bands compared with the Z-bands 
in control cells[72], as well as distorted desmosomes 
associated with accumulation of lipid droplets, that 
were strongly enhanced in lipogenic media[72,73]. 
Relevant to this point, the addition of the GSK-3β 
inhibitor BIO strongly suppress the effects of the 
lipogenic stress[73].
The phenotypic study of CMs derived from the 
patient carrying the homozygous mutation led to 
similar conclusions: an abnormal translocation 
of plakoglobin proteins associated with very low 
β-catenin activity[74]. In addition, the culture of 
these ARVC-CMs, devoid of a correct PKP2 carboxy 
terminus, in a lipogenic medium additionally 
containing PPAR-γ activating drugs, demonstrated 
exaggerated lipogenesis and pronounced apoptosis, 
that can be prevented by the addition of PPAR-γ 
antagonists[74]. Similar results were obtained with 
CMs derived from the patient carrying a heterozygous 
c.2013delC mutation[74].
The rescue of the pathogenic phenotypes was 
achieved by introducing the wild-type PKP2 gene 
back into mutant hiPSC-CMs, thus suggesting 
that mutation of PKP2 is sufficient to induce the 
pathological features observed in ARVC-CMs[74].
Interestingly, the same cells were used by Cerrone 
et al[76] to verify a PKP2-mediated modulation of 
INa: indeed, as already shown using other cellular 
systems, ARVC-CMs showed drastically reduced INa 
and the deficit was restored by re-introducing the 
wild type PKP2 gene.
conclusion 
Since the discovery of the cellular reprogramming 
method followed by in vitro CM differentiation, several 
findings regarding human cardiac cells, especially 
those exhibiting a pathological phenotype, have been 
made possible. We can discuss how close or how far 
is the relation between hiPSC-CMs and the normal 
counterpart, but surely the possibility to obtain 
human CMs in a culture dish is adding a missing item 
to the scientific community. Every model has its own 
limitations and this is true also for hiPSC-CMs. Indeed, 
data from the literature reports the most evident and 
predictable phenotypes, leaving aside those perhaps 
more interesting but still unexplainable. However, as 
shown, many patients’ features are found in these 
hiPSC-CMs, starting from the prolongation of the 
APD corresponding to the elongation of the cardiac 
QT interval, or EAD or DAD events equivalent to 
arrhythmic episodes, or the presence of cellular lipid 
droplets primarily found in cardiac biopsies of patients 
with ARVC[77].
Human CMs have been derived also from cells of 
patients carrying other genetic disorders involving 
cardiac pathologies such as Leopard syndrome[78], 
Pompe disease[79], Duchenne muscular dystrophy[80], 
Friedreich’s ataxia[81], and Fabry disease[82].
In all of the cases, patients-derived CMs showed 
the main characteristic traits of the related pathology: 
hypertrophic cells in Leopard[78]; lower β-glucosidase 
activity, lower markers of metabolism, and higher 
glycogen content in Pompe[79]; a dystrophic gene 
expression profile in Duchenne[80]; impaired mito-
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chondrial homeostasis in Friedreich’s ataxia[81]; 
and globotriaosylceramide accumulation in Fabry 
disease[82]. Moreover, patients-derived CMs represent 
a powerful model to test type and dosage of clinically 
used drugs, laying the basis for a personalized therapy.
Increasing the number and diversifying the 
type of modeled patients will surely improve the 
understanding of the biological mechanism that leads 
to the considered disease. Nevertheless the big ongoing 
efforts reside in eliminating any kind of interaction of 
the reprogramming technology with patient’s DNA and 
in identifying an easily reproducible protocol that leads 
to CM differentiation. Then, the non integrative Sendai-
based reprogramming approach, followed by a chemical 
defined differentiation medium will surely solve the 
issue of reproducible cardiomyocyte differentiation.
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